Found: 152
Select item for more details and to access through your institution.
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 7, p. 833, doi. 10.1177/13524585241242050
- By:
- Publication type:
- Article
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 4/5, p. 558, doi. 10.1177/13524585241234783
- By:
- Publication type:
- Article
A cross‐sectional study of MRI features and the gut microbiome in pediatric‐onset multiple sclerosis.
- Published in:
- Annals of Clinical & Translational Neurology, 2024, v. 11, n. 2, p. 486, doi. 10.1002/acn3.51970
- By:
- Publication type:
- Article
Simulation‐based effect size analysis in the absence of drug effects to inform the design of clinical trials in Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074336
- By:
- Publication type:
- Article
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 14, p. 1795, doi. 10.1177/13524585231205708
- By:
- Publication type:
- Article
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 6, p. 680, doi. 10.1177/13524585231162262
- By:
- Publication type:
- Article
Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 6, p. 741, doi. 10.1177/13524585231162586
- By:
- Publication type:
- Article
Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
- Published in:
- Journal of Neurology, 2023, v. 270, n. 3, p. 1286, doi. 10.1007/s00415-022-11488-y
- By:
- Publication type:
- Article
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 3, p. 385, doi. 10.1177/13524585221144742
- By:
- Publication type:
- Article
Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 2, p. 212, doi. 10.1177/13524585221137500
- By:
- Publication type:
- Article
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 13, p. 2027, doi. 10.1177/13524585221110585
- By:
- Publication type:
- Article
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1927, doi. 10.1177/13524585221097561
- By:
- Publication type:
- Article
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1944, doi. 10.1177/13524585221102584
- By:
- Publication type:
- Article
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 11, p. 1697, doi. 10.1177/13524585221093789
- By:
- Publication type:
- Article
How patients with multiple sclerosis acquire disability.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
- Published in:
- Journal of Neurology, 2022, v. 269, n. 9, p. 5093, doi. 10.1007/s00415-022-11166-z
- By:
- Publication type:
- Article
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1526, doi. 10.1177/13524585221076717
- By:
- Publication type:
- Article
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1591, doi. 10.1177/13524585221083194
- By:
- Publication type:
- Article
Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 801, doi. 10.1177/13524585211037909
- By:
- Publication type:
- Article
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 4, p. 1810, doi. 10.1007/s12325-022-02068-7
- By:
- Publication type:
- Article
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.852563
- By:
- Publication type:
- Article
Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.
- Published in:
- Frontiers in Neurology, 2022, v. 13, p. 1, doi. 10.3389/fneur.2022.809273
- By:
- Publication type:
- Article
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
- Published in:
- European Journal of Neurology, 2021, v. 28, n. 11, p. 3722, doi. 10.1111/ene.15009
- By:
- Publication type:
- Article
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 13, p. 2062, doi. 10.1177/1352458520988637
- By:
- Publication type:
- Article
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 12, p. 1948, doi. 10.1177/1352458521989090
- By:
- Publication type:
- Article
Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 10, p. e2128871, doi. 10.1001/jamanetworkopen.2021.28871
- By:
- Publication type:
- Article
Slowly expanding lesions are a marker of progressive MS – No.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 11, p. 1681, doi. 10.1177/13524585211017020
- By:
- Publication type:
- Article
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 10, p. 1497, doi. 10.1177/1352458520972573
- By:
- Publication type:
- Article
Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise.
- Published in:
- Brain Communications, 2021, v. 3, n. 3, p. 1, doi. 10.1093/braincomms/fcab176
- By:
- Publication type:
- Article
Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Author Correction: Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG MS study.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 6, p. 922, doi. 10.1177/1352458520936934
- By:
- Publication type:
- Article
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420982134
- By:
- Publication type:
- Article
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22265-2
- By:
- Publication type:
- Article
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420987941
- By:
- Publication type:
- Article
Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 2, p. 208, doi. 10.1177/1352458520912172
- By:
- Publication type:
- Article
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 1, p. 48, doi. 10.1001/jamaneurol.2020.2950
- By:
- Publication type:
- Article
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420982134
- By:
- Publication type:
- Article
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420987941
- By:
- Publication type:
- Article
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 13, p. 1729, doi. 10.1177/1352458519881761
- By:
- Publication type:
- Article
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
- Published in:
- JAMA Neurology, 2020, v. 77, n. 9, p. 1132, doi. 10.1001/jamaneurol.2020.1568
- By:
- Publication type:
- Article
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420915005
- By:
- Publication type:
- Article
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor (BTKI) Evobrutinib in Relapsing Multiple Sclerosis over 108 Weeks: Open-Label Extension to a Phase 2 Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 87
- By:
- Publication type:
- Article
Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis.
- Published in:
- Annals of Clinical & Translational Neurology, 2020, v. 7, n. 5, p. 767, doi. 10.1002/acn3.51045
- By:
- Publication type:
- Article
Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes.
- Published in:
- JAMA Neurology, 2020, v. 77, n. 1, p. 82, doi. 10.1001/jamaneurol.2019.2940
- By:
- Publication type:
- Article
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2020, v. 13, p. 1, doi. 10.1177/1756286420915005
- By:
- Publication type:
- Article
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 14, p. 1915, doi. 10.1177/1352458518814117
- By:
- Publication type:
- Article
White matter plasticity and maturation in human cognition.
- Published in:
- Glia, 2019, v. 67, n. 11, p. 2020, doi. 10.1002/glia.23661
- By:
- Publication type:
- Article
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 12, p. 1605, doi. 10.1177/1352458518796675
- By:
- Publication type:
- Article